Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Investigational new drug, company code: BGG492 · 2 trials · 3 indications
| Arm | Type | Description |
|---|---|---|
| BGG492 low dose | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| BGG492 high dose | EXPERIMENTAL | - |
| BGG492 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Investigational new drug, company code: BGG492 | DRUG | - |
| Placebo | DRUG | - |
Inclusion Criteria: * Outpatients ≥ 50 kg (110 lb) of weight. * A diagnosis of epilepsy (≥ 2 years prior to screening) with partial seizures with or without secondarily generalized seizures. * Uncontrolled partial seizures despite having been treated with at least two different antiepileptic drugs ...
BGG492 is an investigational small molecule being studied for the treatment of seizures, specifically partial onset seizures. It has been evaluated in patients with refractory partial seizures and as an adjunctive treatment in partial onset seizures. The drug is in Phase 2 clinical development and is not yet approved.
BGG492 is being developed by Novartis AG, a multinational pharmaceutical company traded on the New York Stock Exchange under the ticker symbol NVS. The drug is currently in Phase 2 clinical trials for the treatment of partial onset seizures.
BGG492 is in Phase 2 clinical development. Two Phase 2 trials have been completed, one evaluating efficacy in refractory partial seizures and another assessing efficacy and safety as an adjunctive treatment in partial onset seizures. The drug remains investigational and has not received regulatory approval.
BGG492 has been studied in two completed Phase 2 trials. NCT00887861 enrolled 37 participants with refractory partial seizures in Germany. NCT01147003 enrolled 93 participants with partial onset seizures across multiple countries including the United States, Bulgaria, Germany, Hungary, Italy, Poland, Slovakia, South Korea, Switzerland, and Taiwan.
BGG492 is not FDA approved. It is an investigational drug currently in Phase 2 clinical development for partial onset seizures. Both completed trials were Phase 2 studies, and the drug has not yet progressed to later-stage trials or regulatory submission.